NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









InGel Therapeutics

InGel Therapeutics

Private
MassachusettsHealthcare & Life Scienceshttps://www.ingeltx.com/

Last Round

Grant

Dec 2, 2024

Total Funding Raised

$13.48M

Company Overview

InGel Therapeutics is a biotechnology company developing engineered cell therapies designed to target neuroprotective pathways to treat retinal degeneration.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Advanced Materials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Revenue Share

AI Layer

Application

Keywords

cell therapyregenerative medicineRetinitis Pigmentosaregen medretinal degenerationbiomimetic hydrogelmutation-agnostic therapyneuroprotectionrod precursor cellshydrogel deliverydrug discovery platformage-related macular degenerationAMDglaucomaAI drug discoveryintravitreal injectionsingle-cell analysisophthalmology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

InGel Therapeutics Comparables

Compare InGel Therapeutics with similar companies based on industry and business-model similarity.

InGel Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
jCyte, Inc.
85%
Nanoscope Therapeutics Inc.
82%
Agnos Therapeutics
81%

InGel Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 2, 2024
SeedJul 1, 2024
GrantMay 4, 2023
AcceleratorSep 1, 2022

Key People

Founding team and executive leadership

Deepti Singh

Founder And Chief Scientific Officer

Founding Team

Pierre Colombe Dromel

CTO And Co-founder

Founding Team

InGel Therapeutics Investors

Notable investors and investment history

InGel Therapeutics investors
InvestorRounds
Bertarelli FoundationGrant
ARPA-HGrant
The Venture CollectiveSeed
NucleateAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 10, 2025

    Monthly visitors grew 51% MoM, from 885 to 1.3K.

  • Jul 8, 2025

    Monthly visitors increased 45% MoM.

InGel Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

InGel Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about InGel Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersMassachusetts
Employee Range8
Year Founded2022
Last FundingDec 2, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.